CStone Pharmaceuticals (HKG:2616) Chief Executive Officer Jianxin Yang increased his holding in the drug company by 560,000 shares, according to a Wednesday filing with the Hong Kong bourse.
Yang purchased the shares at a price ranging from HK$2.26 to HK$3.29 apiece, the filing said.
Since beginning in his role as CEO, Yang has bought 10,359,000 shares, or 5.46% of the total shareholding of CStone.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。